Professional Title and Current Role
David Matthews, PhD, was appointed Chief Business Officer at Beacon Biosignals on February 1, 2024. Beacon Biosignals is a leading company specializing in computational neurodiagnostics and EEG analytics, with a mission to leverage brain data to transform diagnosis and treatment of neurological and neuropsychiatric disorders. Matthews’ role involves overseeing commercial and strategic activities, drawing upon his extensive expertise in healthcare strategy, commercial development, and computational neuroscience.
Professional Background and Experience
David Matthews brings over 20 years of experience in life sciences and healthcare, blending scientific and strategic expertise:
- He holds an A.B. in Molecular Biology with honors from Princeton University, complemented by certificates in Neuroscience and Bioengineering, including graduate-level coursework.
- Prior to his current position, Matthews served as Chief Growth Officer (CGO) and Chief Commercial Officer (CCO) at BrightInsight, a leading digital health platform focused on regulated Software as a Medical Device (SaMD). His tenure there lasted four years until early 2024.
- Before BrightInsight, he was a Partner at Boston Consulting Group (BCG), where he specialized in healthcare strategy, digital transformation, commercialization, and corporate finance for healthcare clients.
- His earlier career includes scientific roles as a computational neuroscientist with a notable record of publications and conference proceedings on machine learning and neurobiology.
Areas of Expertise and Strategic Focus
Matthews’ interdisciplinary background positions him uniquely at the intersection of neuroscience, AI, and commercial healthcare innovation. His core areas of expertise and strategic emphasis include:
- Healthcare Strategy and Commercial Development: Leading market-driven growth and business operations in companies operating at the nexus of biotechnology and digital health.
- Computational Neuroscience: Applying AI and neuroanalytics to improve diagnostic capabilities using EEG and brain data.
- Digital Health and Regulatory Innovation: Experience with regulated SaMD products, key for deployment in neurodiagnostics and broader health technology sectors.
- Partnership Development: Beacon Biosignals actively collaborates with top biopharma companies; Matthews' role likely involves deepening strategic partnerships to drive adoption of Beacon’s neuroanalytics platform.
Notable Achievements and Professional Impact
- At Beacon Biosignals, Matthews is instrumental in expanding the commercialization of an innovative neuroanalytics platform that harnesses AI to analyze EEG data, addressing unmet needs in neurological disorder diagnostics.
- Under Matthews’ commercial leadership, Beacon achieved significant regulatory milestones, including receiving the FDA's first PCCP authorization for a sleep-related medical device (SleepStageML™ AI platform), highlighting a successful integration of AI and regulatory compliance.
- His prior roles at BrightInsight and BCG exhibit a track record of commercial growth, digital strategy, and client transformations in the healthcare sector.
- Matthews maintains a broad professional network exceeding 500 LinkedIn connections, evidencing extensive industry access and stakeholder engagement.
Location and Network
- Based in Los Angeles, California, positioning him within a significant hub for biotech and digital health innovation.
- Active on LinkedIn ([linkedin.com/in/dawima](http://www.linkedin.com/in/dawima)) and Twitter/X (@e2pi), where he shares insights on digital health, neurotechnology, and AI-driven innovation.
This profile underscores David Matthews’ capacity to lead strategic business initiatives in neurodiagnostic technologies that integrate AI with computational neuroscience. His background in both science and commercial leadership at digital health organizations equips him to drive Beacon Biosignals’ growth through partnerships, market development, and regulatory advancement, positioning the company at the forefront of neurotechnology innovation.
